Detailansicht

Wissensnetz

Person

Charles Craddock

Onkologe

Name	Charles Craddock
Ort	Birmingham (Wirkungsort) Großbritannien
Akademischer Grad bzw. Titel	Prof.
Beruf	Onkologe (charakteristischer Beruf)
Beziehung	University of Birmingham Leukämie (Thema)
Quelle	Internet: https://www.birmingham.ac.uk/staff/profiles/cancer-genomic/craddock-charles.aspx (Stand: 21.04.2020)
Datensatztyp	Person
GND-Nummer	1208708767
Datensatz-ID	1208708767
Beteiligt an alle anzeigen Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion Impact of ABO-mismatching following HLA-mismatched unrelated donor hematopoietic stem cell transplantation for AML: a report from the ALWP of the EBMT Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Charles Craddock

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance

Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial

Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party

Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission

Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion

Impact of ABO-mismatching following HLA-mismatched unrelated donor hematopoietic stem cell transplantation for AML: a report from the ALWP of the EBMT

Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT

The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party